Author

N. M. Navone

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 3

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 3 Research Focus:cell type annotation· 3 Research Focus:differential expression· 3 Research Focus:clustering· 2 Approach:experimental assay· 2 Organism:human· 2 Research Focus:drug response / drug discovery· 1 Approach:machine learning (classical)· 1

Frequent Co-Authors

C. J. Logothetis· 2 shared Y. Chen· 2 shared A. Aparicio· 1 shared A. Futreal· 1 shared A. M. Aparicio· 1 shared A. Rumandla· 1 shared B. V. Chakravarthi· 1 shared B. Zhang· 1 shared

Activity by Year

2019-2022 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 18 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

C. J. Logothetis

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Integrative analysis of the MD Anderson Prostate Cancer Patient-Derived Xenograft Series (MDA PCa PDX)

N. Anselmino, E. Labanca, X. Song, J. Yang, P. D. Shepherd, J. Dong, R. Kundra, N. Schultz, J. Zhang, J. C. Araujo, A. M. Aparicio, S. K. Subudhi, P. G. Corn, L. L. Pisters, J. F. Ward, , N. M. Navone

The paper characterizes the genomic and transcriptomic landscape of MDA PCa PDX models and develops an organoid platform to study prostate cancer heterogeneity and resistance.

bioRxiv · Jul 21, 2022 · PreprintCancer Biology

Transcriptional Inactivation of TP53 and the BMP Pathway Mediates Therapy-induced Dedifferentiation and Metastasis in Prostate Cancer

H. Han, Y. Wang, J. N. Curto, S. Gurrapu, S. Laudato, A. Rumandla, G. Chakraborty, X. Wang, H. Chen, Y. Jiang, D. Kumar, E. G. Caggiano, B. Zhang, Y. Ji, S. N. Maity, , F. G. Giancotti

The paper identifies a novel subtype of therapy-induced prostate cancer cells with hybrid E/M and stem-like traits, showing their dependency on HER2/3 signaling and resistance to AR inhibition.

bioRxiv · Apr 14, 2021 · PreprintCancer Biology

Pseudogene associated recurrent gene fusion in prostate cancer

B. V. Chakravarthi, P. D. Arachchige, S. Carskadon, S. Kalyana-Sundaram, J. Li, K.-H. H. Wu, D. S. Chandrashekar, J. O. Peabody, H. Stricker, C. Hwang, D. A. Chitale, S. R. Williamson, N. S. Gupta, N. M. Navone, C. Rogers, , N. Palanisamy

The paper identifies and validates a novel gene fusion in prostate cancer involving KLK4 and KLKP1, showing its association with high Gleason grade tumors and potential as a biomarker.

bioRxiv · Jun 11, 2019Cancer Biology